Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Lachaine
J
J
Faculty of Pharmacy, University of Montreal, Que, Canada.
Laurier
C
C
Langleben
A
A
Vaillant
L
L
D000932:Antiemetics / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002170:Canada; D003362:Cost-Benefit Analysis; D006801:Humans; D008787:Metoclopramide / Q000191:economics* / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D017294:Ondansetron / Q000191:economics* / Q000627:therapeutic use; D011788:Quality of Life; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000932:Antiemetics; D000970:Antineoplastic Agents; D017294:Ondansetron; D008787:Metoclopramide